Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Abuckatatime who wrote (179)	1/19/1999 8:31:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 613

Greg, That was my concern...the fact that SUGN doesn't have a vaccine. What do you think about IMCL being the company in this CBS profile. Also, there is TTP to consider. It is my understanding that IMCL had a fantastic presentation at the H&Q conference last week. Whom ever it maybe, I would think that they would be in late stage trials.

To: Abuckatatime who wrote (179)	1/19/1999 9:46:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 613

I've seen quite a few positive sounding posts from the various biotech fellows over on threads such as VD's model portfolio etc regarding Sugen...if you're looking for a biotech in phase III trials with a vaccine, then how about BIOMF? Cell Therapeutics is really the only biotech in my portfolio right now which leans toward focusing on cancer therapies...the company licensed the worldwide rights to a class of compounds called aryl cyclams, which are anti-angiogenesis small molecules. I used to own Repligen and Magainin for anti-angiogeneseis, but settled on ctic for some exposure to that...but mainly I bought since they also have a GvHD drug in phase III, should hear about that one way or the other soon. CTIC also has a water soluble form of Taxol...but I think I already stated that when I first posted my picks here. Finally, ctic is also doing early work with a compound for treating prostate cancer --for those patients which have not responded to conventional therapy. Oh they also will be reporting on AML PIII results, and an acute lung injury drug. cticseattle.com I think Scott and I agree on this one:-) here is an earlier post techstocks.com --eom